KOSDAQBiotech & Pharma258830

Sejong Medical

₩412 0.00%2026-11-18 close
Market Cap
₩31.2B
Turnover
₩0
Volume
0 shares
Shares out.
75.8M
PER
9.8×
PBR
1.1×
EPS
₩42
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Up Three Straight Quarters; Listing Case Still Open

Sejong Medical's quarterly sales and net income attributable to controlling shareholders rose together from the first quarter of 2026, but the court's ruling on the injunction against the June 2026 delisting decision remains the bigger variable.

  1. 1

    Q3 2026 sales of KRW 5.42 billion were the highest of the last five quarters on a filed basis.

  2. 2

    Operating profit of KRW 2.26 billion in 2025 turned positive, yet a net loss attributable to controlling shareholders of KRW 25.45 million kept the company in the red for a third straight year from 2023.

  3. 3

    Q3 2026 net income attributable to controlling shareholders of KRW 3.54 billion exceeded operating profit of KRW 1.38 billion, so non-operating items and taxes need to be read alongside it in the next periodic report.

  4. 4

    The exchange decided on delisting on June 11, 2026; the company filed for an injunction on June 12, and the exchange suspended the delisting and clearing-sale procedures until the court rules.

  5. 5

    Coverage cites the company's domestic market share leadership in its core product lines and its FDA, CE and JFDA certifications as strengths of the core business.

02

Business structure

Sejong Medical is a medical device maker founded in August 2010 whose core business is single-use instruments for laparoscopic surgery. Its main products include single-use trocars, manual single-use retractors, specimen retrieval bags, absorbable staplers and single-port surgical access devices.

Based on 2017 data, the sales mix was trocars at 49%, specimen bags at 29%, staplers at 9% and others at 13%. A company information aggregate as of March 2026 lists Lab bag at 23%, others at 23% and LapSingle at 16% as top items.

Customers are domestic hospitals and overseas distribution partners, and coverage describes the overseas partner network as spanning 36 countries. The 2017 IPO materials described about 38 domestic competitors, with the company holding roughly a 20% share in trocars and about 90% in specimen bags at the time.

A 2025 report described the company as the domestic market share leader in its core product lines and cited FDA, CE and JFDA certifications. R&D spending is 4% of sales or more, and the company holds 84 patents.

After a change of major shareholder, the company invested in new bio businesses, and coverage links the impairment of those investment assets to losses.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.9B₩1.1B23.3%
2025Q4₩4.5B₩700M14.8%
2026Q1₩4.9B₩900M19.0%
2026Q2₩5B₩1.4B28.7%
2026Q3₩5.4B₩1.4B25.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩16.1B-₩1.8B—−11.2%—418.2%
2023₩18B₩2.2B-₩19.2B12.2%−194.2%997.0%
2024₩19B-₩500M-₩65.1B−2.5%−301.5%139.7%
2025₩18.5B₩2.3B-₩25,447,65012.2%−0.1%164.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual sales rose from KRW 16.1 billion in 2022 to KRW 18 billion in 2023 (up 11.9% year on year) and KRW 19 billion in 2024 (up 5.3%), then fell to KRW 18.5 billion in 2025 (down 2.2%). Among 2022 to 2025, 2024 was the largest year and 2022 the smallest.

Operating profit moved from an operating loss of KRW 1.8 billion in 2022 to operating profit of KRW 2.19 billion in 2023, back to an operating loss of KRW 472 million in 2024, and then to operating profit of KRW 2.26 billion in 2025.

The operating margin was 12.2% in 2023, -2.5% in 2024 and 12.2% in 2025, so the core business margin held in a similar range outside 2024.

Net income attributable to controlling shareholders was a loss of KRW 19.2 billion in 2023 and KRW 65.1 billion in 2024, narrowing to a loss of KRW 25.45 million in 2025, and the company has been loss-making for three straight years from 2023.

Net income including non-controlling interests was reported as the same loss amounts for 2023, 2024 and 2025.

The gap between a KRW 472 million operating loss and a KRW 65.1 billion net loss in 2024 points to large non-operating losses, which coverage attributes to the impairment of investment assets held by the company.

Operating cash flow went from negative KRW 429 million in 2022 to positive KRW 2.76 billion in 2023, KRW 2.54 billion in 2024 and KRW 2.33 billion in 2025. The debt ratio fell from 997.0% in 2023 to 139.7% in 2024 and rose to 164.2% in 2025, when total equity was KRW 22.6 billion and total liabilities KRW 37.2 billion.

On a quarterly basis, the fourth quarter of 2025 was the low point with sales of KRW 4.55 billion, followed by KRW 4.87 billion in the first quarter of 2026, KRW 4.95 billion in the second and KRW 5.42 billion in the third, three straight quarters of growth.

Operating profit recovered from KRW 673 million in the fourth quarter of 2025 to KRW 927 million in the first quarter of 2026 and KRW 1.42 billion in the second, then reached KRW 1.38 billion in the third, down 3.3% from the prior quarter but up 20.1% year on year.

Net income attributable to controlling shareholders swung from a loss of KRW 3.2 billion in the fourth quarter of 2025 to KRW 978 million in the first quarter of 2026, then rose to KRW 1.85 billion in the second and KRW 3.54 billion in the third.

The sum of the last four quarters was KRW 3.17 billion, and because third-quarter net income clearly exceeded operating profit, the contribution of non-operating items should be checked in the next periodic report.

05

Industry analysis

Laparoscopic surgery offers less pain, fewer complications and faster recovery than open surgery, which widens the range of procedures where it is used. That trend supports demand for laparoscopic instruments.

Expansion of minimally invasive and robotic surgery is described as a structural growth trend in the global medical device market. A 2017 IPO analysis argued that most products are single-use, which supports steady demand. Competition is split between many domestic players and global multinational device makers.

Expansion of OEM supply to multinational companies was cited as a growth lever in a securities firm analysis at the time of listing. Sales depend on hospital orders, surgical volumes and the progress of overseas regulatory approvals. In the device industry, product licensing and quality standards act as entry barriers.

The number one position in core domestic product lines is a strength, but losses from new bio businesses are a separate variable to read apart from the core operations.

06

Outlook

The full-year 2026 results will first be disclosed in the 2026 annual report, which is due by the end of March 2027. Whether third-quarter 2026 sales growth carries into the fourth quarter is the next checkpoint.

A 2025 report said a re-tender for the sale of management control was under way, and industry commentary at the time held that a change of largest shareholder would raise the chance of keeping the listing. However, on June 11, 2026, the KOSDAQ Committee of the Korea Exchange decided on delisting.

The company filed for an injunction, and the exchange suspended the procedure until the court reaches a conclusion. The network of partners across 36 countries and 84 patents are cited as the basis for overseas sales expansion.

Overseas expansion and new product effects are growth levers the company has cited repeatedly, but the recent quarterly record offers limited verification so far. In the next periodic report, the operating margin holding near the third-quarter level is the point to watch. The outcome of the listing process could change the scope of the business plan itself.

07

Valuation

PER
9.8×
PBR
1.1×
ROE
11.6%
EPS
₩42
BPS
₩389
Dividend per share
₩0

Net income attributable to controlling shareholders over the last four quarters totals KRW 3.17 billion, a small base, so earnings-based multiples can shift sharply with a single quarter's results.

For that reason a single multiple is a limited guide to the share price, and asset-based measures serve as a steadier reference point. The price-to-book ratio sits in a range without a large premium over net asset value.

Still, total liabilities of KRW 37.2 billion against total equity of KRW 22.6 billion at the end of 2025 means financial capacity and the listing process both weigh on the valuation. The company does not pay dividends, so comparisons on a dividend basis carry limited meaning.

Coverage reports that the share price fell 95% from its peak within five years, and it has moved in a low range since. Because the delisting procedure is under way, the valuation framework used for an ordinary operating company cannot be applied as is.

Whether the quarterly profit recovery continues in the next periodic report is the starting point for reading the multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Quarterly turnaround

Sales rose for three consecutive quarters from the first quarter of 2026 through the third, and the third-quarter figure of KRW 5.42 billion is the largest of the last five quarters on a filed basis.

Operating profit was KRW 1.42 billion in the second quarter and KRW 1.38 billion in the third, above the KRW 673 million of the fourth quarter of 2025. Net income attributable to controlling shareholders turned positive in the first quarter and reached KRW 3.54 billion in the third.

Improved financial structure

The debt ratio, total liabilities divided by total equity, fell from 997.0% in 2023 to 139.7% in 2024 and stood at 164.2% at the end of 2025. Total equity was KRW 22.6 billion and total liabilities KRW 37.2 billion at the end of 2025.

Operating cash flow stayed positive, at KRW 2.76 billion in 2023, KRW 2.54 billion in 2024 and KRW 2.33 billion in 2025.

Domestic share and overseas certifications

Coverage says the company keeps the number one domestic market share in its core product lines and holds FDA, CE and JFDA certifications from the US, Europe and Japan. Its 84 patents and partner network across 36 countries are cited as a base for overseas expansion. R&D spending is 4% of sales or more. OEM supply to multinational companies has been cited as a growth lever since the listing.

09

Bear factors

Delisting procedure under way

The Korea Exchange decided on delisting at its KOSDAQ Committee meeting on June 11, 2026. The company filed for an injunction with the Seoul Southern District Court on June 12, and the exchange suspended delisting and clearing-sale procedures the same day until the court rules. Coverage says the final decision on whether the company stays listed now rests with the court.

Sales decline and continued net losses

Sales in 2025 were KRW 18.5 billion, down 2.2% year on year. Operating profit in 2025 was positive at KRW 2.26 billion, yet a net loss attributable to controlling shareholders of KRW 25.45 million left the company in the red for a third straight year from 2023.

The KRW 65.1 billion net loss in 2024 was far larger than the KRW 472 million operating loss, which points to non-operating losses weighing heavily on that year.

Investment losses and shareholder base

Coverage reports that the value of investment assets held after the company's push into new bio businesses was impaired, causing heavy losses. Coverage also reports that the share price fell 95% from its peak over five years.

As of the end of June 2026, minority shareholders numbered 30,837, or 99.99% of all shareholders, and held 64.29% of the shares.

10

Risk factors

Listing and legal process

The injunction result will determine whether the company stays listed and when trading could resume. If the court does not grant the request, the delisting procedure could resume, and its timing has not been set. A longer process could keep constraints on fundraising and trading liquidity in place.

Volatility from non-operating items

In 2024 an operating loss of KRW 472 million coincided with a net loss of KRW 65.1 billion, while in the third quarter of 2026 net income attributable to controlling shareholders of KRW 3.54 billion exceeded operating profit of KRW 1.38 billion.

If a large share of profit comes from items outside the core business, quarterly earnings swing more widely. The line-item detail of non-operating gains and losses in periodic reports needs to be checked.

Product concentration and regulatory approval

Sales are concentrated in a few laparoscopic product lines, so the business is sensitive to surgical volumes and hospital orders. Medical devices must meet product licensing and quality standards, so approval delays or quality problems can strain delivery schedules. As overseas sales grow, exchange rates and partner inventories also weigh on results.

11

What to watch next

  1. Court ruling date (to be set)

    The Seoul Southern District Court's ruling on the injunction against delisting. The outcome determines whether the company stays listed and whether clearing-sale trading resumes.

  2. By March 31, 2027

    The 2026 annual report, which will first disclose fourth-quarter and full-year 2026 results and the audit opinion. It is the point to check whether the quarterly recovery through the third quarter of 2026 holds on an annual basis.

  3. By May 15, 2027

    The first-quarter 2027 periodic report. It shows whether the operating margin trend and non-operating items continue at the third-quarter 2026 level.

  4. Date to be determined

    Whether the sale of management control is revived or the largest shareholder changes. A 2025 report cited a re-tender, and a change of largest shareholder was presented as a variable in whether the listing can be kept.

12

Overall view

Sejong Medical's filed results moved from an operating loss in 2022 to a profit in 2023, a loss in 2024 and a profit in 2025, and quarterly sales and operating profit in 2026 show a recovery.

Sales peaked at KRW 19 billion in 2024 and eased to KRW 18.5 billion in 2025, while the net loss attributable to controlling shareholders has run for three straight years from 2023. On the financial side, the debt ratio fell from 997.0% in 2023 to 164.2% in 2025, and operating cash flow has been positive since 2023.

However, the delisting decision of June 11, 2026 has been made, and the listing status is not settled until the injunction is decided. A shareholder base in which minority holders account for 99.99% and the history of bio investment losses remain as risks.

Strengths include third-quarter sales growth and domestic product share, while weaknesses include the listing procedure and three straight years of net losses.

The next checkpoints are the court's injunction ruling, the full-year results and audit opinion in the 2026 annual report, and the first-quarter 2027 periodic report. This report offers no investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.fnguide.com
  2. thevaluenews.co.kr
  3. investing-for-everyone.com
  4. etoday.co.kr
  5. edaily.co.kr
  6. ssl.pstatic.net
  7. ssl.pstatic.net
  8. etoday.co.kr
  9. etoday.co.kr
  10. investing.com
  11. jobkorea.co.kr
  12. ilyoseoul.co.kr
  13. catch.co.kr
  14. newsis.com
  15. dailyinvest.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis